ISPE announced the results of its 2021–2022 International Board of Directors election, revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors. The election is run by an independent third party who provides ISPE with the final audited results.
The Board is responsible for the governance and strategic direction of the Society and will assume their elected positions at the 2021 ISPE Annual Meeting & Expo, taking place from 31 October–3 November in Boston, Massachusetts, USA.
The following pharmaceutical industry leaders have been elected to the 2021–2022 ISPE International Board of Directors:
Officers:
Jörg Zimmermann
Chair
Vice President, Vetter Development Service, External Affairs
Vetter Pharma-Fertigung GmbH & Co.
Michael L. Rutherford
Vice Chair
Executive Director, Computer Systems Quality & Data Integrity
Syneos Health
Scott W. Billman
Treasurer
Global Head of Engineering
Jeffrey A. Biskup, PE
Secretary
CEO and Chairman of the Board
CRB
Joanne R. Barrick, RPh
Past Chair
Advisor, Global Validation
Eli Lilly and Company
Re-elected Directors
Ylva Ek
Chief Quality Officer (CQO)
KeyPlants AB
Lou W. Kennedy
CEO and Owner
Nephron Pharmaceuticals
New Directors
Georg Singewald, PhD
VP, Head of Global Quality Control
Genentech, A Member of the Roche Group
Timothy J.N. Watson, PhD
Executive Director & Team Leader, CMC Advisory Office
Pfizer Inc
Board Members Continuing a Term in 2021-2022
In addition to those named above, the following Directors were elected in 2020 to serve a two-year term and will continue their service on the Board:
Vivianne J. Arencibia
Independent Consultant
Arencibia Quality Compliance Associates
Nina S. Cauchon, PhD
Director Regulatory Affairs – CMC
Amgen Inc.
Chris Chen, PhD
CEO
WuXi Biologics (Shanghai) Co., Ltd.
David Doleski
Compliance Head for Biologics Quality Operations
Sanofi
Teresa Minero
Founder & CEO
LifeBee – Digitalizing Life Sciences
Hirofumi Suzuki, PhD
Product Supply Japan, Head of Product Supply Coordination
Bayer Yakuhin Ltd
